A recent report by STAT looks at how synchronous price hikes on key drugs leaves patients struggling to manage the rising costs.
According to the report, drugmakers AbbVie and Amgen in 2013 posted identical price increases, 6.9 percent, on two separate biologics used to treat arthritis and other related conditions. Abbvie increased Humira’s price on Jan. 3, with Amgen the next day hiking the price of Enbrel.
“The pattern repeated 10 more times between 2014 and early 2018,” the report states. “In every instance, prices of both drugs jumped by nearly the same percentage, usually within days of each other … .”
The drugmakers ceased price increases at the same amount: $63,363.